✦ LIBER ✦

Twelve-year mortality results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for postmenopausal early-stage breast carcinoma patients (SITAM 01)

✍ Scribed by Carol Alliot

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 41 KB
Volume: 107
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.21960

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Twelve-year mortality results of a rando

Twelve-year mortality results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for postmenopausal early-stage breast carcinoma patients (SITAM 01)

✍ Maurizio Belfiglio; Miriam Valentini; Fabio Pellegrini; Giorgia De Berardis; Mon 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 1 views

## Abstract ## BACKGROUND This study evaluated the impact on overall survival (OS) of 2 versus 5 years adjuvant tamoxifen in early breast carcinoma patients after 12 years of follow‐up. ## METHODS Women with breast carcinoma T1–3, N0–3, M0, aged 50–70 years, were eligible for this multicenter ra

A randomized trial of long term adjuvant

A randomized trial of long term adjuvant tamoxifen plus postoperative radiation therapy versus radiation therapy alone for patients with early stage breast carcinoma treated with breast-conserving surgery

✍ Kristina Dalberg; Hemming Johansson; Ulla Johansson; Lars E. Rutqvist 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB 👁 2 views

## BACKGROUND. The use of adjuvant tamoxifen to treat postmenopausal breast carcinoma patients as an adjunct to primary surgery is well established. The current study reports the long term results for a low risk stratum in a randomized trial of adjuvant tamoxifen. The main focus of this analysis w